Multiple sclerosis (MS), an idiopathic autoimmune disease of a chronic and progressive nature, with an affinity for the central nervous system, often results in disability. The condition displays a global rise in incidence and prevalence, affecting around 1.8 million people worldwide. A higher incidence is seen in developed regions of the world and in countries further away from the equator. Females display a higher predisposition for developing MS in comparison to men, with a ratio of 2:1. Therapeutic developments have progressed rapidly from the 1960s to current times, aiding in slowing progression, and alleviating symptoms experienced by MS patients. Currently, as no cure is available, the key area for growth remains targeting the progression, as well as degenerative changes of MS. The McDonald Criteria aim to reduce disability and extend survival rates in patients with MS. Its combination of good clinical practice with radiological, neurological, ophthalmic, and biochemical test findings, for the early diagnosis of MS, enhances patient care and quality of life. More promising and alternative treatment options for MS, including Bruton’s tyrosine kinase inhibitors, stem cell transplants, and chimeric antigen receptor T cell therapy, are currently undergoing trials. Ebstein-Barr virus vaccines have also been found to decrease the incidence of MS. In collaboration with organizations such as the WHO (world health organization) and MSIF (multiple sclerosis international federation), such advancements in knowledge about the pathogenesis and mechanisms by which MS occurs allow us to view the evolving possibilities of possible prevention, diagnosis, and management of the disease (Tafti, Ehsan, Xixis, Multiple sclerosis, StatPearls, https://www.ncbi.nlm.nih.gov/books/NBK499849/ , 2024; Tardo, Multiple sclerosis spotlight: Early diagnosis, better treatments, and hope for MS-free future | Back and Spine | Brain | UT Southwestern Medical Center, 2021; Cleveland Clinic, Multiple Sclerosis, 2024).